A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery

A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery

Clifford L Salinger,1 Michael Gordon,2 Mitchell A Jackson,3 Theodore Perl,4 Eric Donnenfeld5 1VIP Laser Eye Center, Palm Beach Gardens, FL, 2Gordon Weiss Schanzlin Vision Institute, San Diego, CA, 3Jacksoneye, Lake Villa, IL, 4Corneal Associates of New Jersey, Fairfield, NJ, 5Ophthalmic Consultants...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Salinger CL, Gordon M, Jackson MA, Perl T, Donnenfeld E
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2015
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/2b1fc380eb3c433ba1caf78ed2b76c70
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:2b1fc380eb3c433ba1caf78ed2b76c70
record_format dspace
spelling oai:doaj.org-article:2b1fc380eb3c433ba1caf78ed2b76c702021-12-02T06:11:48ZA retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery1177-5483https://doaj.org/article/2b1fc380eb3c433ba1caf78ed2b76c702015-11-01T00:00:00Zhttps://www.dovepress.com/a-retrospective-analysis-of-the-postoperative-use-of-loteprednol-etabo-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Clifford L Salinger,1 Michael Gordon,2 Mitchell A Jackson,3 Theodore Perl,4 Eric Donnenfeld5 1VIP Laser Eye Center, Palm Beach Gardens, FL, 2Gordon Weiss Schanzlin Vision Institute, San Diego, CA, 3Jacksoneye, Lake Villa, IL, 4Corneal Associates of New Jersey, Fairfield, NJ, 5Ophthalmic Consultants of Long Island, Garden City, NY, USA Background: While loteprednol etabonate ophthalmic gel 0.5% (LE gel) is approved for treatment of postoperative ocular inflammation and pain, there have been no reported studies in patients undergoing laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK).Methods: This was a retrospective chart review conducted at five refractive surgical centers in the USA. Data were collected from primary LASIK or PRK surgery cases in which LE gel was used postoperatively as the clinician’s routine standard of care and in which patients were followed-up for up to 6 months. Data extracted from charts included patient demographics, surgical details, LE gel dosing regimen, pre- and postsurgical refractive characteristics, intraocular pressure (IOP) measurements, and visual acuity. Primary outcomes included postoperative IOP elevations, adverse events, and early discontinuations.Results: Data were collected on 189 LASIK eyes (96 patients) and 209 PRK eyes (108 patients). Mean (standard deviation [SD]) years of age at surgery was 36.0 (11.7) and 33.9 (11.3) in LASIK and PRK patients. LE gel was prescribed most often four times daily during the first postoperative week, regardless of procedure; the most common treatment duration was 7–14 days in LASIK and ≥30 days in PRK patients. No unusual corneal findings or healing abnormalities were reported. Mean postoperative uncorrected distance visual acuity was 20/24 in LASIK and 20/30 in PRK eyes. Mild/trace corneal haze was reported in 20% of PRK patients; two PRK patients with moderate/severe corneal haze were switched to another corticosteroid. Mean postoperative IOP did not increase over time in either LASIK or PRK eyes (P≥0.331); clinically significant elevations from baseline in IOP (≥10 mmHg) were noted in only three eyes of two PRK patients.Conclusion: LE gel appears to have a high level of safety and tolerability when used for the management of postoperative pain and inflammation following LASIK and PRK surgery. Keywords: loteprednol etabonate, intraocular pressure, chart review, safety, postoperative pain and inflammationSalinger CLGordon MJackson MAPerl TDonnenfeld EDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 2089-2097 (2015)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Salinger CL
Gordon M
Jackson MA
Perl T
Donnenfeld E
A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
description Clifford L Salinger,1 Michael Gordon,2 Mitchell A Jackson,3 Theodore Perl,4 Eric Donnenfeld5 1VIP Laser Eye Center, Palm Beach Gardens, FL, 2Gordon Weiss Schanzlin Vision Institute, San Diego, CA, 3Jacksoneye, Lake Villa, IL, 4Corneal Associates of New Jersey, Fairfield, NJ, 5Ophthalmic Consultants of Long Island, Garden City, NY, USA Background: While loteprednol etabonate ophthalmic gel 0.5% (LE gel) is approved for treatment of postoperative ocular inflammation and pain, there have been no reported studies in patients undergoing laser-assisted in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK).Methods: This was a retrospective chart review conducted at five refractive surgical centers in the USA. Data were collected from primary LASIK or PRK surgery cases in which LE gel was used postoperatively as the clinician’s routine standard of care and in which patients were followed-up for up to 6 months. Data extracted from charts included patient demographics, surgical details, LE gel dosing regimen, pre- and postsurgical refractive characteristics, intraocular pressure (IOP) measurements, and visual acuity. Primary outcomes included postoperative IOP elevations, adverse events, and early discontinuations.Results: Data were collected on 189 LASIK eyes (96 patients) and 209 PRK eyes (108 patients). Mean (standard deviation [SD]) years of age at surgery was 36.0 (11.7) and 33.9 (11.3) in LASIK and PRK patients. LE gel was prescribed most often four times daily during the first postoperative week, regardless of procedure; the most common treatment duration was 7–14 days in LASIK and ≥30 days in PRK patients. No unusual corneal findings or healing abnormalities were reported. Mean postoperative uncorrected distance visual acuity was 20/24 in LASIK and 20/30 in PRK eyes. Mild/trace corneal haze was reported in 20% of PRK patients; two PRK patients with moderate/severe corneal haze were switched to another corticosteroid. Mean postoperative IOP did not increase over time in either LASIK or PRK eyes (P≥0.331); clinically significant elevations from baseline in IOP (≥10 mmHg) were noted in only three eyes of two PRK patients.Conclusion: LE gel appears to have a high level of safety and tolerability when used for the management of postoperative pain and inflammation following LASIK and PRK surgery. Keywords: loteprednol etabonate, intraocular pressure, chart review, safety, postoperative pain and inflammation
format article
author Salinger CL
Gordon M
Jackson MA
Perl T
Donnenfeld E
author_facet Salinger CL
Gordon M
Jackson MA
Perl T
Donnenfeld E
author_sort Salinger CL
title A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
title_short A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
title_full A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
title_fullStr A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
title_full_unstemmed A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
title_sort retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
publisher Dove Medical Press
publishDate 2015
url https://doaj.org/article/2b1fc380eb3c433ba1caf78ed2b76c70
work_keys_str_mv AT salingercl aretrospectiveanalysisofthepostoperativeuseofloteprednoletabonategel05followinglaserassistedinsitukeratomileusisorphotorefractivekeratectomysurgery
AT gordonm aretrospectiveanalysisofthepostoperativeuseofloteprednoletabonategel05followinglaserassistedinsitukeratomileusisorphotorefractivekeratectomysurgery
AT jacksonma aretrospectiveanalysisofthepostoperativeuseofloteprednoletabonategel05followinglaserassistedinsitukeratomileusisorphotorefractivekeratectomysurgery
AT perlt aretrospectiveanalysisofthepostoperativeuseofloteprednoletabonategel05followinglaserassistedinsitukeratomileusisorphotorefractivekeratectomysurgery
AT donnenfelde aretrospectiveanalysisofthepostoperativeuseofloteprednoletabonategel05followinglaserassistedinsitukeratomileusisorphotorefractivekeratectomysurgery
AT salingercl retrospectiveanalysisofthepostoperativeuseofloteprednoletabonategel05followinglaserassistedinsitukeratomileusisorphotorefractivekeratectomysurgery
AT gordonm retrospectiveanalysisofthepostoperativeuseofloteprednoletabonategel05followinglaserassistedinsitukeratomileusisorphotorefractivekeratectomysurgery
AT jacksonma retrospectiveanalysisofthepostoperativeuseofloteprednoletabonategel05followinglaserassistedinsitukeratomileusisorphotorefractivekeratectomysurgery
AT perlt retrospectiveanalysisofthepostoperativeuseofloteprednoletabonategel05followinglaserassistedinsitukeratomileusisorphotorefractivekeratectomysurgery
AT donnenfelde retrospectiveanalysisofthepostoperativeuseofloteprednoletabonategel05followinglaserassistedinsitukeratomileusisorphotorefractivekeratectomysurgery
_version_ 1718400041578659840

Ejemplares similares